Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Lung gene expression of ApoE-/- mice in an 8-month inhalation study to assess exposure effects for a candidate modified risk tobacco product, THS 2.2 compared with conventional cigarettes


ABSTRACT: Cigarette smoking is a major risk factor for the development and progression of diseases such as cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD). Modified risk tobacco products (MRTP) are designed to reduce smoking-related health risks. Suitable animal models are important for understanding smoke-induced pathogenesis. Over an 8-month period, hallmarks of both COPD and CVD were investigated in ApoE?/? mice exposed to conventional cigarette smoke (CS) or to an aerosol from a candidate MRTP, the tobacco heating system (THS2.2). In addition to chronic exposure, cessation or switching to THS2.2 after 2 months of CS were investigated.ᅠ In a systems toxicology approach, classical end points (e.g., physiology, histology) were complemented with transcriptomics, lipidomics, and proteomics analyses. CS induced nasal epithelial hyperplasia and metaplasia, lung inflammation, and emphysematous changes (impaired pulmonary function, alveolar damage). Atherogenic effects of CS exposure were altered lipid profiles and increased aortic plaque formation. Exposure to THS2.2 aerosol (nicotine concentration matched to CS ヨ 29.9 mg/m3) did not induce lung inflammation and emphysema, nor did it consistently change the lipid profile or enhance the plaque area. Cessation and switching caused reversal of inflammatory responses and no progression of initial emphysematous changes and aortic plaque area. Biological processes, e.g., senescence, inflammation, proliferation, were significantly impacted in 3R4F-exposed, but not in THS2.2-exposed tissues. Cessation or switching reduced these perturbations to become nearly indistinguishable from sham-exposure. In conclusion, the mouse model indicated retarded progression of atherosclerotic and emphysematous changes upon cessation or switching to THS2.2 which alone had no adverse effects.

ORGANISM(S): Mus musculus

SUBMITTER: Vincenzo Belcastro 

PROVIDER: E-MTAB-3681 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2017-08-05 | E-MTAB-5280 | biostudies-arrayexpress
2015-11-30 | PXD002530 | Pride
2017-02-27 | E-MTAB-3900 | biostudies-arrayexpress
2016-10-31 | E-MTAB-3876 | biostudies-arrayexpress
2017-04-01 | E-MTAB-5609 | biostudies-arrayexpress
2017-04-01 | E-MTAB-5608 | biostudies-arrayexpress
2019-04-18 | E-MTAB-7444 | biostudies-arrayexpress
2019-04-18 | E-MTAB-7892 | biostudies-arrayexpress
2016-12-22 | PXD002925 | Pride
2021-08-16 | E-MTAB-7981 | biostudies-arrayexpress